Search

Displaying results 4031 - 4040 of 9322 in total
  1. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy.

  2. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects. … R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  3. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    [A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears to carry the most potent anti-tumour activity.[A186802,A186805] … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_.

  4. Drug

    Iohexol

    go.drugbank.com/drugs/DB01362
    ApprovedInvestigational

    Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

  5. Drug

    Estramustine phosphate

    go.drugbank.com/drugs/DB14674
    Approved

    A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

  6. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

  7. Drug

    Progabide

    go.drugbank.com/drugs/DB00837
    Experimental

    It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors.

  8. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  9. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC). … Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs

  10. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.